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Abstract
Purpose Cabozantinib is a multi-kinase inhibitor that targets MET, AXL, and VEGFR2, and may synergize with
EGFR inhibition in NSCLC. Cabozantinib was assessed
alone or in combination with erlotinib in patients with progressive NSCLC and EGFR mutations who had previously
received erlotinib.
Methods This was a phase Ib/II study (NCT00596648).
The primary objectives of phase I were to assess the safety,
pharmacokinetics, and pharmacodynamics and to determine maximum tolerated dose (MTD) of cabozantinib plus
erlotinib in patients who failed prior erlotinib treatment. In
phase II, patients with prior response or stable disease with
erlotinib who progressed were randomized to single-agent
cabozantinib 100 mg qd vs cabozantinib 100 mg qd and
erlotinib 50 mg qd (phase I MTD), with a primary objective of estimating objective response rate (ORR).

These data were presented in part at the American Society
for Clinical Oncology (ASCO) annual meeting in June 2010,
Chicago, IL.

Results Sixty-four patients were treated in phase I. Doses
of 100 mg cabozantinib plus 50 mg erlotinib, or 40 mg
cabozantinib plus 150 mg erlotinib were determined to be
MTDs. Diarrhea was the most frequent dose-limiting toxicity and the most frequent AE (87.5% of patients). The ORR
for phase I was 8.2% (90% CI 3.3–16.5). In phase II, one
patient in the cabozantinib arm (N = 15) experienced a partial response, for an ORR of 6.7% (90% CI 0.3–27.9), with
no responses for cabozantinib plus erlotinib (N = 13). There
was no evidence that co-administration of cabozantinib
markedly altered erlotinib pharmacokinetics or vice versa.
Conclusions Despite responses with cabozantinib/erlotinib in phase I, there were no responses in the combination arm of phase II in patients with acquired resistance to
erlotinib. Cabozantinib did not appear to re-sensitize these
patients to erlotinib.
Keywords Non-small cell lung cancer · Resistance ·
Cabozantinib · Erlotinib · Phase Ib/II · Combination
therapy

Electronic supplementary material The online version of this
article (doi:10.1007/s00280-017-3283-z) contains supplementary
material, which is available to authorized users.
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Erlotinib and other epidermal growth factor receptor
(EGFR) tyrosine kinase inhibitors (TKIs) are established
first-line treatments for patients with non-small cell lung
cancer (NSCLC) with activating mutations in EGFR.
Despite response rates of 60–70% with EGFR TKIs in
this patient population, the median progression-free survival (PFS) with these agents remains under 1 year [1] due
to the development of acquired resistance [2, 3] through
secondary resistance mutations (e.g., T790M) [4–8] and
emergence of bypass signaling pathways such as vascular endothelial growth factor (VEGF) and MET [2, 7–11].
Data suggest that dual inhibition of the VEGF and EGFR
pathways can delay the development of resistance to EGFR
TKIs in the upfront setting [12] but may not overcome
acquired resistance [13], whereas targeting MET has been
shown to re-sensitize tumors resistant to EGFR TKIs in
preclinical models [14].
Cabozantinib is a small-molecule inhibitor of multiple
tyrosine kinases including MET, AXL, VEGF receptors
(VEGFRs), and RET [15]. The drug has been approved by
the US Food and Drug Administration (FDA) for the treatment of progressive, metastatic medullary thyroid cancer
[16, 17] and, more recently, for advanced renal cell carcinoma after prior anti-angiogenic therapy [18, 19].
Preclinical studies in NSCLC suggest a potential for
cabozantinib to re-sensitize tumors to EGFR inhibitors. The
addition of cabozantinib to gefitinib had no notable impact
on activity in a gefitinib-sensitive NSCLC cell line but resensitized a gefitinib-resistant cell line [14]. Furthermore,
the combination of cabozantinib and erlotinib demonstrated
substantially increased anti-tumor activity over either agent
administered alone in a MET-amplified NSCLC xenograft
model resistant to EGFR inhibition.
Based on the hypothesis that the expression of MET and
VEGF are mechanisms of acquired resistance to EGFR
TKIs in NSCLC tumors [2, 9, 11, 20], the phase Ib/II
study reported here tested whether cabozantinib, alone or
in combination with continued EGFR inhibition, was tolerable and active in patients with advanced NSCLC who
had progressed after benefiting from erlotinib therapy. The
study was designed to first determine the maximum tolerated dose (MTD) of cabozantinib and erlotinib in combination and then to assess the safety and clinical activity of the MTD combination compared with single-agent
cabozantinib.

informed consent for this trial according to international
guidelines. The protocol was reviewed and treatment was
monitored by institutional review boards at each participating institution, and the study adhered to the principles of the
Guideline for Good Clinical Practice (International Conference on Harmonisation E6 Tripartite Guideline). The trial
is registered at ClinicalTrials.gov (NCT00596648).
Eligible patients had histologically confirmed Stage
IIIb or IV NSCLC. Patients were at least 18 years old, had
adequate organ and marrow function with an absolute neutrophil count ≥1500/mm3, platelets ≥100,000/mm3, hemoglobin ≥9 g/dL, bilirubin ≤1.5 times the upper limit of
normal (ULN), serum creatinine ≤1.5 mg/dL or calculated
creatinine clearance ≥60 mL/min, and alanine aminotransferase and aspartate aminotransferase ≤2.5 times ULN.
Patients with uncontrolled brain metastases, clinically
significant hemoptysis, and hematemesis were excluded.
Patients were also excluded for the presence of cavitary
pulmonary lesion(s), endobronchial lesion or a lesion abutting a major blood vessel, pregnancy or lactation, serious
intercurrent illness, uncontrolled hypertension [sustained
blood pressure (BP) readings of >140 mmHg systolic or
>90 mmHg diastolic], unhealed wounds from recent surgery, or congestive heart failure, unstable angina, or clinically significant cardiac arrhythmias within 3 months, or
transient ischemic attack, stroke, or myocardial infarction
within 6 months. Anti-cancer therapy, other than erlotinib
(or gefitinib in phase II), was not allowed within 4 weeks
prior to entry.
In addition to these eligibility criteria, patients enrolled
in phase I must have failed prior treatment with erlotinib
but tolerated erlotinib at a dose greater than or equal to the
dose of the cohort in which they were assigned. Patients
had to have an Eastern Cooperative Oncology Group
(ECOG) performance status of ≤2.
For phase II, patients had to have measurable disease per
Response Evaluation Criteria in Solid Tumors (RECIST)
guidelines, version 1.0 [21] and an ECOG performance
status of ≤1. Patients were also required to have had progressed during treatment with erlotinib after either an initial response or at least 6 months of stable disease. Patients
were also required to have amylase and lipase <1.5 times
the ULN. Patients were excluded for prior therapy with a
VEGFR TKI, an investigational EGFR TKI, a MET inhibitor, recent history (3 months) of radiation therapy other
than to bones, or a history of idiopathic pulmonary fibrosis
or interstitial lung disease.

Patients and methods

Treatment plan and study design

This was a multicenter, phase Ib/II, open-label study
of cabozantinib and erlotinib. All patients gave written

In both phase I and II, erlotinib and cabozantinib were
given orally (po) once daily (qd). Cabozantinib was
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supplied as 20- and 80-mg capsules (expressed as the freebase equivalent weight). Erlotinib 25-, 100-, and 150-mg
tablets were available commercially. Screening was conducted within 28 days before the first dose of study drug.
Each cycle was 4 weeks (28 days).
Safety was assessed at frequent intervals by standard
clinical and laboratory tests, physical examinations, and
12-lead electrocardiograms. All adverse events (AEs) were
graded according to the National Cancer Institute Common
Terminology Criteria for Adverse Events (NCI-CTCAE),
version 3.0. Radiographic tumor assessments were conducted at baseline (within 7 days before first dose in phase
II) and every 8 weeks after the initiation of study treatment
per RECIST guidelines, version 1.0 [21].
Phase I was a 3 + 3 dose escalation/de-escalation design
in 2 parallel arms: Arm A maximized the dose of cabozantinib [to a maximum dose of 140 mg qd (the single-agent
MTD)] [22], and Arm B maximized the dose of erlotinib
[to a maximum dose of 150 mg qd (the label dose for
NSCLC)] [23]. Primary objectives in phase I were to evaluate the safety and tolerability of cabozantinib and erlotinib
administered in combination, to determine a MTD of the
combination, and to characterize the pharmacokinetic (PK)
parameters of single-agent erlotinib (run-in period) and
cabozantinib in combination with erlotinib. Exploratory
objectives included the assessment of objective response
rate (ORR). Erlotinib was administered as a single agent on
days −14 to −1 (run-in period) at the dose used during subsequent treatment with the combination. After PK evaluation of erlotinib alone on day 1, cabozantinib was administered in combination with erlotinib qd in 28-day cycles.
Dose-limiting toxicity (DLT) was defined as any of the
following that occurred during the first 28 days of treatment: a treatment-emergent AE that warranted dose reduction or was of significant risk; non-hematologic significant grade 3/4 toxicity, including grade 3 diarrhea despite
prophylaxis and other optimal treatment; intolerable rash;
grade 4 thrombocytopenia, grade 4 neutropenia of >5 days
duration or grade 3/4 neutropenia with fever and documented infection; inability to take >75% of planned study
dose owing to an AE; or inability to start Cycle 2 within
28 days of planned start date because of an AE. Events
clearly unrelated to either cabozantinib or erlotinib were
not considered DLTs. The MTD was defined as a dose level
below the maximum administered dose in which <30%
of the total patients in the expanded cohort experienced a
DLT.
For the initial dose cohort (Cohort 1), the dose levels
for the combination were cabozantinib 60 mg qd + erlotinib 150 mg qd (Table 1). The protocol was subsequently
amended to allow for the 2 parallel-dose de-escalation/
dose escalation arms. In Arm A, the dose of erlotinib
was reduced below the approved/label dose of 150 mg qd
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Table 1  Phase I dose-level cohorts
Cohort

Initial dose (mg)a

1
2A
2B
3A
4A

60 cabozantinib, 150 erlotinib
60 cabozantinib, 100 erlotinib
40 cabozantinib, 150 erlotinib
100 cabozantinib, 100 erlotinib
100 cabozantinib, 50 erlotinib

a

All cabozantinib doses are expressed as the freebase equivalent
weight

(initially to 100 mg qd) and the initial dose of cabozantinib
was maintained at 60 mg qd and increased as tolerated in
subsequent cohorts to a maximum of 140 mg qd. In Arm
B, the dose of erlotinib was maintained at the approved/
label dose of 150 mg qd and the dose of cabozantinib was
40 mg qd. At the investigator’s discretion, patients could
continue to receive cabozantinib after the DLT evaluation
period either alone or in combination with erlotinib, provided that there was no evidence of progressive disease
(PD) or unacceptable study drug-related toxicity.
Phase II was a Simon optimal 2-stage design in which
patients were randomized in a 1:1 fashion to receive single-agent cabozantinib at 100 mg qd or the combination of
cabozantinib 100 mg qd plus erlotinib 50 mg qd based on
the phase I Arm A MTD. The phase I MTD of Arm B was
not further evaluated in phase II. Initial enrollment in each
arm (Stage I) was estimated at 15 patients to ensure 12 were
evaluable for response. If there was ≥1 responder in Stage
I, enrollment could be expanded in that arm (Stage II). In
phase II, the primary objective was to estimate the ORR.
Secondary objectives included the evaluation of safety and
tolerability, evaluation of PFS, and characterization of PK
parameters of cabozantinib and erlotinib.
Crossover was permitted during phase II at the discretion of the investigator. Patients treated in the single-agent
cabozantinib arm who developed PD had the option to
cross over to receive combination cabozantinib/erlotinib,
whereas those receiving cabozantinib/erlotinib who experienced PD had the option to cross over to single-agent cabozantinib (at a dose greater than what they were receiving in
the combination). Patients who crossed over could continue
until they experienced unacceptable toxicity or treatment
failure as defined by investigator assessment.

Pharmacokinetics
Blood samples for PK assessments were taken at predetermined intervals. In phase I, PK assessments were conducted at 15 min before dose and then after dose at 30 min
and 1, 2, 4, 8, and 24 h on day −1 and C2D1 (day 29);
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before dose and 4 h after dose on C2D15 (day 43); before
dose approximately every 2 cycles (every 8 weeks) starting
with C3D1 (day 57) to coincide with routine tumor assessments; and at a 30-day post-treatment visit or study withdrawal. In phase II, blood samples were collected 15 min
before dose and 4 h after dose on C1D1, C1D15, C2D1,
and C2D15, then every 2 cycles (8 weeks) starting with
C3D1 to coincide with routine tumor assessments, ideally
at the time of withdrawal from the trial.
Cabozantinib and erlotinib concentrations in plasma
were determined using a validated liquid chromatography–mass spectrometry method at Exelixis, Inc. All concentrations were reported in units of ng freebase/mL. The
lower limit of quantification for both analytes was 0.5 ng
freebase/mL. Data assembly was performed using S-Plus®
8.0 for Windows (Enterprise Version, Tibco Software Inc.,
Palo Alto, CA). WinNonlin Professional 5.2 (Pharsight
Corp., Mountain View, CA) was used for calculating the
summary statistics and generating raw tables. Concentration–time profiles and other PK-related plots were generated using S-Plus Version 8.0 for Windows.
Statistical considerations
The safety population consists of all patients who received
study treatment. The efficacy-measurable population was
defined as patients with measurable disease at baseline.
The safety population was used for all analyses except
ORR, which used the efficacy-measurable population. Best
overall response and ORR were summarized using frequency counts and percentages, and the 90% confidence
interval was computed using the exact binomial distribution. Median duration of response and the associated
90% confidence intervals (CIs) were calculated using the
Kaplan–Meier method.
For patients who had a crossover in phase II, both efficacy and safety data are summarized up to the time of
crossover. For all other patients, study data are summarized
up to 30 days after the last dose of study drug.
Statistical analyses of safety, PK, and pharmacodynamic
data were performed with WinNonlin Enterprise, version
5.0.1 (Pharsight Corp, Mountain View, CA), GraphPad
Prism (version 4.02) software, SoftMaxPro GxP (version
5), and/or SAS (version 9.1).

Results
A total of 65 patients were enrolled in phase I, and 64
patients received combination treatment with cabozantinib/
erlotinib and were included in the analysis. One patient
received erlotinib during the 14-day run-in period but withdrew owing to PD before receiving cabozantinib. Baseline
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characteristics are summarized in Table 2. In phase I, the
median patient age was 59.8 years (range 30–88 years), and
44 patients (68.8%) were female. The majority of patients
(43/64; 67.2%) were white; 17 (26.6%) were Asian. At
baseline, all patients except 2 had an ECOG performance
status of 0 or 1. The majority of patients (82.8%) had
adenocarcinoma. All patients had metastatic disease at
study entry for an average of >2 years from initial diagnosis, including 14% with brain metastases. The majority
of patients in phase I had at least 3 anti-cancer regimens
before enrolling in the study, and 63 patients (98.4%) had
previously been treated with erlotinib.
In phase II, 28 patients received treatment with single-agent cabozantinib (n = 15) or cabozantinib/erlotinib (n = 13). The median age was 54.7 years (range
36–74 years) in the cabozantinib arm and 64.8 years (range
44–78 years) in the combination arm. Twelve patients
(80.0%) in the cabozantinib arm and 7 patients (53.8%) in
the combination arm were female. The majority of patients
were white [10/15 (66.7%) cabozantinib arm and 8/13
(61.5%) combination arm]; 4 (26.7%) in the cabozantinib
arm and 3 (23.1%) in the combination arm were Asian.
The majority of patients (93.3% receiving cabozantinib
and 84.6% in the combination arm) had adenocarcinoma.
All patients had metastatic disease at study entry, including 25% with brain metastases. Similar to phase I, the mean
years since the initial diagnosis of metastasis was >2 years,
with the majority having received at least 3 prior anti-cancer regimens. An activating EGFR mutation was detected
in 10 of the patients in the cabozantinib arm and 7 in the
combination arm; EGFR mutation status was unknown for
the remaining 11 patients.

Phase I MTD
DLTs from phase I of the trial are shown in Table 3. Fifteen
patients experienced a DLT. Diarrhea was the most frequently observed DLT across all cohorts (10 patients experienced a DLT of diarrhea ranging from grade 2 to 3). Two of
3 patients enrolled in Cohort 1 (60-mg cabozantinib/150-mg
erlotinib) experienced a DLT of diarrhea (1 with grade 2 and
1 with grade 3). The patient with grade 3 diarrhea also experienced grade 3 aspartate aminotransferase elevation and
grade 3 palmar-plantar erythrodysesthesia syndrome (PPES).
In Cohort 2A (60-mg cabozantinib/100-mg erlotinib), 5 of
16 patients experienced DLTs: 4 patients with grade 3 diarrhea and 1 with grade 2 diarrhea. In Cohort 3A (100-mg
cabozantinib/100-mg erlotinib), 5 of 15 patients experienced a DLT: grade 3 diarrhea and grade 3 fatigue (n = 1),
grade 3 fatigue (n = 1), grade 3 lipase elevation (n = 1),
grade 3 hypertension (n = 1), and grade 3 hypokalemia
(n = 1). The Cohort 3A dose exceeded the defined MTD.

Cancer Chemother Pharmacol (2017) 79:923–932
Table 2  Demographic and
baseline characteristics: phase I
and II (safety populations)
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Phase I
(N = 64)

Age (years)
Median (range)
59.8 (30–88)
Age category, n (%)
18–<25 years
0
25–<45 years
6 (9.4)
45–<65 years
35 (54.7)
≥65 years
23 (35.9)
Sex, n (%)
Male
20 (31.3)
Female
44 (68.8)
ECOG performance status, n (%)
0
26 (40.6)
1
36 (56.3)
2
1 (1.6)
Missing
1 (1.6)
Race, n (%)
Asian
17 (26.6)
Black or African American
2 (3.1)
White
43 (67.2)
Not reported
1 (1.6)
Other
1 (1.6)
Histology, n (%)
Adenocarcinoma
53 (82.8)
Squamous cell carcinoma
3 (4.7)
Large cell carcinoma
1 (1.6)
Other
7 (10.9)

Phase II
Cabozantinib
(N = 15)

Cabozantinib/erlotinib
(N = 13)

54.7 (36–74)

64.8 (44–78)

0
2 (13.3)
10 (66.7)
3 (20.0)

0
1 (7.7)
6 (46.2)
6 (46.2)

3 (20.0)
12 (80.0)

6 (46.2)
7 (53.8)

5 (33.3)
10 (66.7)
0
0

2 (15.4)
11 (84.6)
0
0

4 (26.7)
1 (6.7)
10 (66.7)
0
0

3 (23.1)
1 (7.7)
8 (61.5)
1 (7.7)
0

14 (93.3)
1 (6.7)
0
0

11 (84.6)
2 (15.4)
0
0

ECOG Eastern Cooperative Oncology Group

A total of 14 patients were enrolled in Cohort 4A (100-mg
cabozantinib/50-mg erlotinib), with no patients experiencing a DLT. Based on the frequencies of DLTs in Arm A, the
Cohort 4A dose level was declared the MTD of Arm A.
In Arm B, 17 patients were enrolled in Cohort 2B (40mg cabozantinib/150-mg erlotinib), 3 of whom experienced DLTs: grade 3 diarrhea (n = 2) and grade 3 stomatitis
(n = 1). The Cohort 2B dose level was determined to be the
MTD of Arm B.

Safety and tolerability
Phase I
Treatment-emergent AEs (any grade) reported by at least
15% of patients in phase I are summarized in supplementary Table S1. The most common (>35%) AEs of any
grade were diarrhea, decreased appetite, fatigue, nausea,
rash, and weight decrease. Twenty patients (31.3%) had a

≥30-mmHg increase in systolic BP from baseline, and 17
patients (26.6%) had a ≥20-mmHg diastolic BP increase
from baseline (supplementary Table S2). Grade 3/4 AEs
were experienced by 87.5% of patients (Table 4). Diarrhea (45.3%), fatigue (21.9%), and hypokalemia (14.1%)
were the most common grade 3/4 events. Twelve patients
(18.8%) experienced an AE leading to drug discontinuation, with diarrhea and PPES being the most common
(10.9 and 3.1%, respectively).
There were 13 deaths within 30 days of the last dose of
study treatment. One death was attributed to respiratory
arrest and another to asystole/coronary artery atherosclerosis and cardiac arrest; both were considered unrelated
to study treatment. The remaining 11 deaths were attributed to PD. One patient who died of PD experienced a
fatal pulmonary hemorrhage (day 26 after the last dose),
which was assessed as possibly related to study treatment.
Three additional grade 5 AEs reported in patients who
died of PD were pneumonia, cardio-respiratory arrest,
and respiratory failure, all unrelated to study treatment.
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Table 3  Cabozantinib phase I DLTs
Cohort

Dose (mg)
Cabozantinib

N

Patients with DLTs

DLTsa

Diarrhea, grade 2
Diarrhea, grade 3
Increase AST,
grade 3
PPES, grade 3
Diarrhea, grade 3
(n = 4)
Diarrhea, grade 2
Diarrhea, grade 3
(n = 2)
Mucositis, grade 3
Hypokalemia,
grade 3
Hypertension,
grade 3
Diarrhea, grade 3
Fatigue, grade 3
(n = 2)
Lipase, grade 3
Epigastric pain,
grade 3
N/A

Erlotinib

1

60

150

3

2

2A

60

100

16

5

2B

40

150

17

3

3A

100

100

15

5

4A

100

50

14

0

AST aspartate aminotransferase, DLT dose-limiting toxicity, PPES palmar-plantar erythrodysesthesia syndrome
a

One event for each DLT unless otherwise specified

Phase II
The most commonly reported AEs (>35%) in phase II
were fatigue, diarrhea, nausea, decreased appetite, and
PPES (supplementary Table S3). Differences were noted
between treatment arms in the frequency of some AEs,
including diarrhea (46.7% cabozantinib vs 84.6% cabozantinib/erlotinib), dehydration (13.3 vs 46.2%), vomiting
(20.0 vs 38.5%), cough (53.3 vs 7.7%), and constipation
(40.0 vs 15.4%). Eleven patients (73.3%) in the cabozantinib arm and 13 patients (100%) in the combination arm
experienced at least 1 grade 3 or 4 AE (Table 5), with 53.3
and 84.6% experiencing a treatment-related grade 3 or 4
AE, respectively. Rates of grade 3/4 AEs differed between
single-agent cabozantinib vs the combination for diarrhea
(0 vs 30.8%), dehydration (0 vs 23.1%), and lymphopenia
(0 vs 15.4%). Four patients (26.7%) in the cabozantinib arm
and 3 (23.1%) in the combination arm had a ≥30-mmHg
systolic BP increase from baseline; 8 patients (53.3%) and
4 patients (30.8%), respectively, had a ≥20-mmHg diastolic
BP increase from baseline (supplementary Table S4).
The rate of dose modification (dose interruption or reduction) due to AEs was 66.7% for cabozantinib and 69.2% for
cabozantinib/erlotinib and was primarily due to PPES (33.3
vs 23.1%) and diarrhea (6.7 and 38.5%). The most common reason for treatment discontinuation was PD (80.0% on
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cabozantinib and 46.2% on the combination). Discontinuation due to AEs occurred in 2 (13.3%) patients receiving
cabozantinib (fatigue and non-fatal hemorrhagic stroke) and
5 patients (38.5%) receiving the combination (PPES, large
intestine perforation, fatigue/diarrhea/weight loss, transient
ischemic attack, and intracranial hemorrhage). Three patients
in the cabozantinib arm died within 30 days of receiving their last dose of study drug, all from PD. There were
2 deaths from PD and clinical deterioration within 30 days
of last receiving the combination study dose that were not
considered to be related to study treatment. The intracranial
hemorrhage leading to discontinuation in the combination
arm was considered treatment-related and was fatal.

Efficacy
Phase I
The efficacy-measurable population included 61 patients
across the dose cohorts. Five patients experienced a partial
response (PR) for an ORR of 8.2% [90% confidence interval (CI) 3.3, 16.5%], with no apparent trend by dose level.
The median PFS was 3.7 months (95% CI 3.2, 5.5 months).
The overall median duration of treatment for cabozantinib was 3.6 months (range 0.1–36.0 months), or

Cancer Chemother Pharmacol (2017) 79:923–932
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Table 4  Treatment-emergent grade 3 or 4 adverse events reported by
≥5% of patients: phase I (safety population)

Phase II

Preferred term, n (%)

N = 64

Any treatment-emergent adverse event
Diarrhea
Fatigue
Hypokalemia
Dyspnea
Pneumonia
Decreased appetite
Hypophosphatemia
Hypertension
Pulmonary embolism
Weight decreased
Dehydration
Hyponatremia
Hypoxia
Pain
Back pain
Hypomagnesemia
Blood potassium decreased
Lipase increased
Renal failure acute
Palmar-plantar erythrodysesthesia syndrome
Thrombocytopenia

56 (87.5)
29 (45.3)
14 (21.9)
9 (14.1)
7 (10.9)
6 (9.4)
5 (7.8)
5 (7.8)
5 (7.8)
5 (7.8)
5 (7.8)
4 (6.3)
4 (6.3)
4 (6.3)
4 (6.3)
3 (4.7)
3 (4.7)
3 (4.7)
3 (4.7)
3 (4.7)
3 (4.7)
3 (4.7)

One of 15 patients in the single-agent cabozantinib arm
achieved a confirmed PR for an ORR of 6.7% (90% CI
0.3, 27.9%), whereas there were no responses in the cabozantinib/erlotinib arm. The median PFS was 1.9 months
(95% CI 1.6, 7.1 months) for the cabozantinib arm and
3.9 months (95% CI 1.5, 7.3 months) for the combination
arm.
The overall median duration of treatment for cabozantinib (not including treatment after crossover) was 2.1
months (range 0.2–16.6 months) or approximately 2 cycles
of study treatment in both treatment arms. Cumulatively,
there were 18 patients (64.3%) who were on study treatment for ≥8 weeks (2 cycles), 12 patients (42.9%) on study
treatment for ≥12 weeks (3 cycles), and 9 patients (32.1%)
on study treatment for ≥16 weeks (4 cycles).
Eight patients crossed over from cabozantinib to cabozantinib/erlotinib after experiencing PD. The patient who
achieved a PR with single-agent cabozantinib progressed
and crossed over to receive cabozantinib/erlotinib (PFS
duration of 16.6 months prior to crossover) and subsequently transitioned to the cabozantinib maintenance protocol continuing treatment for an additional 18+ months.
Despite the PR in the single-agent cabozantinib arm,
expansion of the arm did not proceed owing to logistical
issues and prioritization of resources and not because of
unexpected safety concerns or lack of efficacy.

Table 5  Treatment-emergent grade 3 or 4 adverse events in ≥2
patients: phase II (safety population)
Preferred term, n (%)

Hypertension
Hyponatremia
Fatigue
Hypokalemia
Diarrhea
Dehydration
Lymphopenia

Cabozantinib
(N = 15)

Cabozantinib
+ erlotinib
(N = 13)

2 (13.3)
2 (13.3)
2 (13.3)
1 (6.7)
0
0
0

1 (7.7)
1 (7.7)
1 (7.7)
2 (15.4)
4 (30.8)
3 (23.1)
2 (15.4)

approximately 4 cycles of study treatment. The majority
of patients (57.8%) were treated until disease progression
per RECIST guidelines, version 1.0. Cumulatively, there
were 45 patients (70.3%) who were on study treatment for
≥8 weeks (2 cycles) and 31 patients (48.4%) on study treatment for ≥16 weeks (4 cycles). One patient with prolonged
stable disease and 1 patient with prolonged objective
response (each with a PFS duration of >1000 days and on
study treatment >35 cycles) were eventually transitioned
onto a cabozantinib maintenance protocol and continued on
therapy for an additional 18+ months.

Pharmacokinetics
During phase Ib of the study, available PK results were
analyzed for each dosing cohort at the time of the cohort
review committee meetings to assess for any apparent
drug–drug interaction between cabozantinib and erlotinib.
Co-administration of cabozantinib (in a dose range of
40–100 mg) and erlotinib (in a dose range of 50–150 mg)
had no apparent effect on plasma area under the curve of
each agent compared with that agent administered alone.
Formal PK analysis was conducted in phase II of the
study. In phase II, with all patients in the single-agent arm
receiving cabozantinib 100 mg po qd, the mean ± standard
deviation (SD) pre-dose plasma concentration of cabozantinib was 996 ± 513 ng/mL and 846 ± 335 ng/mL on day 15
(C1D15) and day 29 (C2D1), respectively. Dose normalization of these means (i.e., dividing by 100 mg) resulted in
values that were generally consistent with dose-normalized
results seen for other cabozantinib studies [22]. Steady
state was reached by about day 15. Approximately fourfold
plasma accumulation of cabozantinib was observed in this
study based on the day 29:day 1 concentration at 4 h postdose ratio, which was generally consistent with the results
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reported in other studies. Plasma concentrations of cabozantinib were maintained over an extended dosing period
(through study day 60) for both the single-agent cabozantinib and cabozantinib/erlotinib arms during phase II (data
not shown). No marked difference in plasma cabozantinib
concentration was seen between the cabozantinib vs cabozantinib/erlotinib arms; there was no evidence to suggest
that co-administration of erlotinib markedly altered cabozantinib PK.
Interpatient variability (coefficient of variance, CV%) in
erlotinib pre-dose concentrations (79.8 and 59.8% on day
15 and day 29, respectively) was consistent with the published values [24, 25]. Furthermore, the mean dose-normalized erlotinib pre-dose concentration on day 15 (i.e.,
355 ng/mL for 50-mg erlotinib = 7.1 ng/mL/mg) was generally consistent with the published results for steady-state
erlotinib minimum concentration (Cmin), in which a mean
value of approximately 7.5 ng/mL/mg was observed across
the 50–200 mg erlotinib dose groups on day 24 [24, 25].
Taken together, there was no evidence to suggest that coadministration of cabozantinib markedly altered erlotinib
PK.

Discussion
Multiple strategies to overcome resistance to EGFR TKIs
have been explored over the past decade. The multi-TKI
cabozantinib, with potent MET/AXL/VEGFR2 blockade,
seemed an ideal compound alone or in combination with
erlotinib to overcome secondary erlotinib resistance. As
discovered in this phase Ib/II trial, however, this strategy
resulted in increased frequency of overlapping toxicities,
most notably, diarrhea. Nevertheless, phase Ib established
2 combination MTDs to bring forward into future trials. Dose escalation was explored in 2 parallel arms, each
maximizing doses of cabozantinib (Arm A) and erlotinib
(Arm B). Dose escalation was limited predominantly by
diarrhea. Eventually, the MTD for the combination of cabozantinib/erlotinib in Arm A was determined to be 100-mg
cabozantinib/50-mg erlotinib (maximizing the cabozantinib
dose) and the MTD in Arm B was determined to be 40-mg
cabozantinib/150-mg erlotinib (maximizing the erlotinib
dose). These MTDs were below the maximum planned
doses, but were based on the toxicities observed in this
trial. Other toxicities were as expected for a combination of
EGFR and VEGFR inhibition, including PPES and hypertension. PK analysis revealed no evidence that co-administration of the agents markedly altered the PK of either drug,
despite both being CYP3A4 substrates.
Phase II evaluated single-agent cabozantinib at 100 mg
and the combination MTD of Arm A from phase I (100-mg
cabozantinib/50-mg erlotinib). Although there was a PR in
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the single-agent cabozantinib arm of phase II, expansion of
that arm into the second stage of enrollment did not occur
for logistical reasons, preventing further assessment of single-agent activity. Toxicity was as expected in phase II. The
most frequent grade 3/4 AEs were hypertension, hyponatremia, and fatigue for the cabozantinib arm and diarrhea
and dehydration for the cabozantinib/erlotinib arm. The
most frequent AE leading to study drug modification in the
cabozantinib arm was PPES, whereas diarrhea, dehydration, and PPES were the most frequent AEs leading to dose
modification in the combination arm.
One treatment-related death occurred in the phase II
cabozantinib/erlotinib arm from an intracranial hemorrhage. Two other patients experienced non-fatal central
nervous system events, 1 with a transient ischemic attack
(combination arm) and 1 with a hemorrhagic stroke (cabozantinib). In phase Ib, 1 patient who died of PD had a
potential treatment-related toxicity of pulmonary hemorrhage nearly a month after study drug discontinuation.
Severe hemorrhage is a rare but potentially fatal complication that has been reported with cabozantinib in other clinical studies; thrombotic events have also been reported [26].
Thus, caution is warranted with this combination.
The ORR for phase I was 8.2% (5 of 61 patients) with
no apparent dose–response trend among the combination
cohorts, but there were no PRs in the 13 patients randomized to the combination arm in phase II. There was 1
responder out of 15 (6.7%) in the phase II single-agent
cabozantinib arm. Almost all patients enrolled in this
study were previously treated with erlotinib; however, only
patients enrolled in phase II were required to have previously experienced a response or prolonged stable disease
and subsequently progressed during erlotinib treatment
(acquired resistance). The addition of cabozantinib to erlotinib in the phase II combination arm did not restore sensitivity to EGFR TKI therapy, although this arm was relatively small.
The limited efficacy of the cabozantinib/erlotinib combination in phase II is perhaps not surprising given the information that has emerged since the initiation of this trial
implicating secondary mutations in EGFR (e.g., T790M) as
a more common resistance mechanism than MET amplification (the rationale for this study) [7]. Other trials focused
on MET inhibition to prevent or delay EGFR TKI resistance have also had limited success [27]. Thus, a study
limitation is the lack of routine testing for EGFR-activating
mutations, which was not standard at the time this trial was
conducted (first patient enrolled February 12, 2008). We
did not verify patient EGFR-activating mutation status, as
patients were selected based on clinical criteria of response
to EGFR TKI (a reasonable surrogate) or at least 6 months
of stable disease on erlotinib before progression, which
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may have allowed a significant number of patients without
true EGFR-activating mutations onto the trial.
As the patients enrolled in the current study were likely
heterogeneous with respect to EGFR mutation status and
mechanisms of resistance to prior EGFR TKI treatment, it is
difficult to draw firm conclusions about the clinical activity of
cabozantinib in EGFR mutant NSCLC. The responses seen
with the combination in phase I and the response seen with
single-agent cabozantinib in phase II supported additional
investigations of cabozantinib in NSCLC. A randomized
discontinuation trial of cabozantinib in unselected patients
with NSCLC reported a single-agent response rate of 10%
[28]. The California Cancer Consortium completed a phase II
study of 37 patients with NSCLC and an EGFR mutation who
had progressed on prior EGFR TKI therapy using the combination dose of 40 mg qd for cabozantinib and 150 mg qd
for erlotinib [29]. The reported toxicities in this phase II
trial were similar to those reported in the current study. The
response rate was 5.4% and the disease control rate (defined
as PR or SD ≥8 weeks) was 67.6%. Furthermore, the role of
VEGF inhibition to delay erlotinib resistance in patients with
EGFR mutation NSCLC recently received renewed interest with publication of a positive phase II trial looking at the
addition of the VEGF antibody bevacizumab to single-agent
erlotinib as a first-line strategy [12]. Taken together, further
exploration of cabozantinib in combination with erlotinib in
patients with EGFR mutations is warranted, possibly selecting patients based on MET expression.
Cabozantinib, with and without erlotinib, also holds
promise in other subsets of NSCLC. Activity with singleagent cabozantinib has been reported in a small series of
patients with NSCLC with translocations in ROS1 [30] or
RET mutations [31]. Specific trials in these patient populations are ongoing or planned. A phase II trial (E1512)
focused on patients with EGFR wildtype disease randomized patients to either erlotinib alone (150 mg po qd),
cabozantinib alone (60 mg po qd), or in combination
(150 mg erlotinib/40 mg cabozantinib), with crossover to
the combination for those with PD on either single agent.
The study showed a significant improvement in PFS and
OS with the cabozantinib-containing arms compared with
single-agent erlotinib; follow-up studies are currently in
development [32]. Correlative analyses of outcomes with
MET, KRAS, and other known driver mutations are ongoing. These additional studies will provide further insight
into a potential role for cabozantinib in the treatment of
NSCLC.
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